Groowe Groowe / Newsroom / SCNX
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

SCNX News

Scienture Holdings, Inc. Common Stock

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

globenewswire.com
SCNX

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

globenewswire.com
SCNX

Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

accessnewswire.com
DGXX DYAI STRT GAME ACNT RNXT DCGO BOSC SCNX ELWT MOB VELO FLUX

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

globenewswire.com
SCNX

iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

accessnewswire.com
DYAI STRT GAME ACNT RNXT DCGO BOSC SCNX ELWT MOB

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

globenewswire.com
SCNX

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

globenewswire.com
SCNX

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

globenewswire.com
SCNX

Wellgistics Health Announces Executive Management and Board Changes

accessnewswire.com
WGRX SCNX WGRX

SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet

globenewswire.com
SCNX